In vitro antimicrobial activity and MIC quality control guidelines of: RPR 106972 (RPR 112808/RPR106950): A novel orally administered streptogramin combination

Diagnostic Microbiology and Infectious Disease

Volumn 28, Issue 3, 1997, Pages 139-147

  Putnam, Shannon D ^a   Jones, Ronald N ^a   Johnson, David M ^a   Washington, J ^b   Murray, P ^c   Knapp, C ^d   Haugen, T ^e   Walker, R ^f  

^a UNIVERSITY OF IOWA   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c BARNES JEWISH HOSPITAL   (United States)

^d Sensititre   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CIPROFLOXACIN; CLAVULANIC ACID; CLINDAMYCIN; DALFOPRISTIN; QUINOPRISTIN; RPR 106950; RPR 106972; RPR 112808; STREPTOGRAMIN; TEICOPLANIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CORYNEBACTERIUM; ENTEROCOCCUS FAECALIS; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; RESPIRATORY SYSTEM; RESPIRATORY TRACT INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; DRUG COMBINATIONS; DRUG RESISTANCE, MICROBIAL; ENTEROCOCCUS; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE COCCI; GUIDELINES; HUMANS; MICROBIAL SENSITIVITY TESTS; QUALITY CONTROL; SPECIES SPECIFICITY; VIRGINIAMYCIN;

EID: 0030763786     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(97)00023-0     Document Type: Article

References (18)

1. Appelbaum PC (1996) Emerging resistance to antimicrobial agents in Gram-positive bacteria. Drugs 51:1-5.
2. Berthaud N, Charles Y, Gouin A-M, Mereau B, Rousseau J, Desnottes J-F (1995) RPR 106972, a new oral streptogramin: In vitro antibacterial activity. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco, CA). Washington, DC: American Society for Microbiology, (abst 112), p. 21.
3. Bootsma HJ, van Dijk H, Verhoef J, Fleer A, Mooi FR (1996) Molecular characterization of the BRO β-lactamase of Moraxella (Branhamella) catarrhalis. Antimicrob Agents Chemother 40:966-972.
4. Cormican MG, Jones RN (1996) Emerging resistance to antimicrobial agents in Gram-positive bacteria. Drugs 51:6-12.
5. Diaz-Linares M, Pendland SL (1996) Post-antibiotic effect (PAE) and time kill (TK) activity of RPR 106972 against Bacteroides fragilis (BF). In Program and Abstracts of the 3rd International Conference on the Macrolides, Azalides, and Streptogramins (Lisbon, Portugal), (abst 6.03).
6. Doern GV, Brueggemann A, Holley Jr HP, Rauch AM (1996) Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: Results of a 30-center national surveillance study. Antimicrob Agents Chemother 40:1208-1213.
7. Finch RG (1996) Antibacterial activity of quinupristin/ dalfopristin: Rationale for clinical use. Drugs 51:31-37.
8. Jones RN, Kehrberg EN, Erwin ME, Anderson SC (1994) Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous centers in the United States. I. Study on the threat of emerging resistances: Real or perceived? Diagn Microbiol Infect Dis 19:203-215.
9. Killian AD, Woodward JG, Rye S, Pendland SL (1996) Bacterial activity of RPR 106972 and erythromycin (ERY) against Legionella pneumophilia (LP). In Program and Abstracts of the 3rd International Conference on the Macrolides, Azalides, and Streptogramins (Lisbon, Portugal), (abst 1.04).
10. McNicholl IR, Pendland SL (1996) Bacterial activity of RPR 106972 and vancomycin, alone and in combination, against methicillin-resistant Staphylococcus aureus (MRSA). In Program and Abstracts of the 3rd International Conference on the Macrolides, Azalides, and Streptogramins (Lisbon, Portugal), (abst 3.24).
11. National Committee for Clinical Laboratory Standards (NCCLS) (1993) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard M7-A3. 3rd edition. Villanova, PA: NCCLS.
12. National Committee for Clinical Laboratory Standards (NCCLS) (1994) Development of in vitro susceptibility testing criteria and quality control parameters: approved guideline M23-A. Villanova, PA: NCCLS.
13. Pankuch GA, Jacobs MR, Appelbaum PC (1996) MIC and time-kill study of antipneumococcal activities of RPR 106972 (a new oral streptogramin), RP 59500 (quinupristin-dalfopristin), pyostacine (RP 7293), penicillin G, cefotaxime, erythromycin, and clarithromycin against 10 penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother 40:2071-2074.
14. Pendland SL, Killian AD, Scrimpsher JG, Rodvold KA (1995) In vitro activity of a new streptogramin, RPR 106972, alone and in combination with rifampin or ciprofloxacin against Legionella. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco, CA). Washington, DC: American Society for Microbiology, (abst 114), p. 23.
15. Rubinstein E, Keller N (1996) Future prospects and therapeutic potential of Streptogramins. Drugs 51:38-42.
16. Sabath LD, Liebeler C, Kelly J (1995) Antistaphylococcal activity of RPR 106972 (RPR 112808/RPR 106950), a new oral streptogramin, compared with that of twelve other antimicrobial agents. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco, CA). Washington, DC: American Society for Microbiology, (abst 111), p. 20.
17. Spangler SK, Jacobs MR, Appelbaum PC (1996) Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother 40:481-484.
18. Vannuffel P, Cocito C (1996) Mechanism of action of streptogramins and macrolides. Drugs 51:20-30.